Skip to content

CORPORATE ACCESS

A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.

Your Search Consumer

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide...

read more

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and...

read more
Arrow